UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack
Glenmark, Teva And Viatris Argue Successfully That Dapagliflozin Patent Invalid
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
